Order by Providence includes wide range of Elekta hardware, software and services STOCKHOLM, April 14 – Elekta announced today that Providence Health & Services (Renton, Washington, USA) – the nation’s third largest not-for-profit health system – has ordered multiple Elekta cancer management solutions, including radiation therapy systems and upgrades, oncology information systems and multiyear service contracts for its hospitals, clinics and other health care facilities in Washington, Alaska, California, Montana and Oregon. In 2012, Providence and Seattle’s Swedish Health Services affiliated, bringing together two of the region’s largest health care organizations. The Swedish Cancer Institute was a long-time partner with Elekta in the provision of cancer management resources in the northwest. “Our new partnership with Providence continues a mutually beneficial tradition in which two organizations work together to build value for thousands of individuals in this region who need world-class health care,” says Jay Hoey, Executive Vice President, Elekta North America. “We’re jointly creating something that is more than a traditional vendor-customer relationship – it’s an alliance of two entities with a common vision to improve patients’ lives.” In the agreement, Providence Health & Services will acquire several Versa HD™ (http://www.versahd.com/) systems, Elekta’s most advanced radiation therapy system (linear accelerator), featuring sophisticated beam shaping technology combined with high dose rate delivery. Versa HD is designed to give clinicians the flexibility to deliver conventional therapies to treat a wide range of small and large tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision. In addition, Elekta will provide upgrades to several existing Elekta systems, including the integration of Agility™ (http://www.elekta.com/agility) 160-leaf multileaf collimator (MLC) and XVI (5.0) (http://www.elekta.com/XVI) software. In a significant acquisition of Elekta software, Providence also will begin a system-wide conversion of its existing oncology information system to MOSAIQ® (http://www.elekta.com/MOSAIQ) Oncology Information System. Installation of the Elekta systems is set to begin immediately, continuing through the end of 2016. # # # For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com Time zone: CET: Central European Time Tobias Bülow, Director Financial Communication, Elekta AB Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com Time zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on April 14, 2015. About Elekta Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
Elekta to deliver advanced cancer management solutions to
Top 10 Most Recent News Articles
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China
Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...
Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull
Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...
Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026
Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...
Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations
ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...
Continue Reading
FFR's Michigan Milestone and Major Robotics Update
Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...
Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue ReadingTop 5 Most Recently Viewed Articles
SRM Entertainment Expands Horizon with Strategic Moves.
SRM Entertainment's Strategic Growth Plans SRM Entertainment, Inc. (Nasdaq: SRM) is taking bold steps to enhance its market position and create long-term value for its shareholders. Despite receiving numerous inquiries from investors regarding potential capital raises, the company has confirmed no immediate plans to seek additional funding. This strategic decision aligns...
Continue Reading
SBA Communications Unveils Tax Reporting Details for 2024
SBA Communications Corporation Announces 2024 Tax Reporting Insights SBA Communications Corporation (Nasdaq: SBAC) has shared important tax reporting information concerning its distributions for 2024. As stockholders prepare for their tax obligations, the company encourages them to seek advice from their personal tax advisors to ensure they understand their specific tax...
Continue Reading
electroCore Achieves Significant Milestone with New Patents
electroCore Enhances Innovation Through New Patents electroCore, Inc. (NASDAQ: ECOR), a leading figure in the bioelectronic medicine and wellness space, has recently made headlines by receiving notifications for five new patents issued by the United States Patent and Trademark Office (USPTO). This expansion of its intellectual property portfolio not only underscores...
Continue Reading
Empowering Grassroots: A Great Idea’s New Microgrant Initiative
Introducing the A Great Idealist Microgrant Program A Great Idea (AGI) has recently unveiled its A Great Idealist Microgrants program, designed to provide crucial financial support to grassroots organizers, community advocates, and innovative leaders across the nation. This initiative echoes AGI's commitment to uplift and empower those at the forefront of social change....
Continue Reading
Elevat and HydraForce Team Up for Game-Changing Solutions
Dynamic Partnership Set to Transform OEM Offerings What’s brewing in the world of industrial machine intelligence? It’s more than a merger—it’s a strategic collaboration that’s about to shake things up. Elevat, that Seattle-based powerhouse known for its cutting-edge solutions, has joined forces with HydraForce, backed by Bosch, to roll out some impressive...
Continue Reading